- Home
- STTK vs PYPD Comparison
STTK vs PYPD Comparison
Compare STTK & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- PYPD
- Stock Information
- Founded
- STTK 2016
- PYPD 2008
- Country
- STTK United States
- PYPD Israel
- Employees
- STTK N/A
- PYPD N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- STTK Health Care
- PYPD Health Care
- Exchange
- STTK Nasdaq
- PYPD Nasdaq
- Market Cap
- STTK 38.4M
- PYPD 36.0M
- IPO Year
- STTK 2020
- PYPD 2020
- Fundamental
- Price
- STTK $0.77
- PYPD $3.44
- Analyst Decision
- STTK Hold
- PYPD Strong Buy
- Analyst Count
- STTK 4
- PYPD 5
- Target Price
- STTK $3.00
- PYPD $11.40
- AVG Volume (30 Days)
- STTK 229.3K
- PYPD 121.3K
- Earning Date
- STTK 08-04-2025
- PYPD 08-13-2025
- Dividend Yield
- STTK N/A
- PYPD N/A
- EPS Growth
- STTK N/A
- PYPD N/A
- EPS
- STTK N/A
- PYPD N/A
- Revenue
- STTK $4,606,000.00
- PYPD N/A
- Revenue This Year
- STTK N/A
- PYPD N/A
- Revenue Next Year
- STTK N/A
- PYPD N/A
- P/E Ratio
- STTK N/A
- PYPD N/A
- Revenue Growth
- STTK 69.65
- PYPD N/A
- 52 Week Low
- STTK $0.69
- PYPD $2.30
- 52 Week High
- STTK $4.51
- PYPD $4.42
- Technical
- Relative Strength Index (RSI)
- STTK 41.85
- PYPD 45.30
- Support Level
- STTK $0.73
- PYPD $3.63
- Resistance Level
- STTK $0.92
- PYPD $3.85
- Average True Range (ATR)
- STTK 0.07
- PYPD 0.17
- MACD
- STTK 0.01
- PYPD -0.03
- Stochastic Oscillator
- STTK 20.80
- PYPD 22.95
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.